Free Trial

Janux Therapeutics (JANX) Stock Price, News & Analysis

Janux Therapeutics logo
$25.49 +1.04 (+4.25%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$24.96 -0.54 (-2.10%)
As of 07/9/2025 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Janux Therapeutics Stock (NASDAQ:JANX)

Key Stats

Today's Range
$24.69
$25.61
50-Day Range
$22.62
$32.88
52-Week Range
$22.48
$71.71
Volume
917,775 shs
Average Volume
868,909 shs
Market Capitalization
$1.51 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$95.25
Consensus Rating
Buy

Company Overview

Janux Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
28th Percentile Overall Score

JANX MarketRank™: 

Janux Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 648th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Janux Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Janux Therapeutics has received no research coverage in the past 90 days.

  • Read more about Janux Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Janux Therapeutics are expected to decrease in the coming year, from ($1.38) to ($2.35) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Janux Therapeutics is -18.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Janux Therapeutics is -18.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Janux Therapeutics has a P/B Ratio of 1.31. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Janux Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    21.42% of the float of Janux Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Janux Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Janux Therapeutics has recently decreased by 0.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Janux Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Janux Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    21.42% of the float of Janux Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Janux Therapeutics has a short interest ratio ("days to cover") of 11.2, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Janux Therapeutics has recently decreased by 0.56%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for JANX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Janux Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Janux Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $206,776.00 in company stock.

  • Percentage Held by Insiders

    Only 8.10% of the stock of Janux Therapeutics is held by insiders.

  • Percentage Held by Institutions

    75.39% of the stock of Janux Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Janux Therapeutics' insider trading history.
Receive JANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Janux Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JANX Stock News Headlines

Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tariffs just lit the fuse. Millions of investors are blindsided as stocks plunge… but this is only Phase 1. If you're still holding the wrong assets, you could lose 30% or more in the coming weeks.
Janux Therapeutics Becomes Oversold (JANX)
See More Headlines

JANX Stock Analysis - Frequently Asked Questions

Janux Therapeutics' stock was trading at $53.54 on January 1st, 2025. Since then, JANX stock has decreased by 52.4% and is now trading at $25.49.

Janux Therapeutics, Inc. (NASDAQ:JANX) issued its quarterly earnings data on Thursday, May, 8th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.05.

Janux Therapeutics (JANX) raised $152 million in an initial public offering on Friday, June 11th 2021. The company issued 9,500,000 shares at a price of $15.00-$17.00 per share. BofA Securities, Cowen and Evercore ISI acted as the underwriters for the IPO and H.C. Wainwright & Co. LLC was co-manager.

Shares of JANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Janux Therapeutics investors own include American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), iShares Micro-Cap ETF (IWC), Voyager Therapeutics (VYGR), Waste Connections (WCN) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/08/2025
Today
7/09/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:JANX
CIK
1817713
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$200.00
Low Price Target
$41.00
Potential Upside/Downside
+273.7%
Consensus Rating
Buy
Rating Score (0-4)
3.09
Research Coverage
11 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$68.99 million
Pretax Margin
-832.71%

Debt

Sales & Book Value

Annual Sales
$10.59 million
Price / Cash Flow
N/A
Book Value
$19.49 per share
Price / Book
1.31

Miscellaneous

Free Float
54,382,000
Market Cap
$1.51 billion
Optionable
Optionable
Beta
2.86
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:JANX) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners